secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-06-10T20:16:40+00:00
Accession:  0001193125-26-265867
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharmaceuticals CMO Anna Eramo resigns; will advise through September 15, 2026
--------------------------------------------------------------------------------

- Anna Eramo, M.D., resigns as CMO effective June 15, 2026; transitions to advisor role through Sept 15, 2026.
- Separation agreement includes base salary until June 15, 2027, prorated 2026 bonus, and accelerated vesting of 66,143 options.
- Company states departure is unrelated to clinical operations and expects no material impact on clinical milestones.
- Search for replacement underway; existing clinical teams will continue to oversee ongoing trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526265867/0001193125-26-265867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526265867/d221514d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-265867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer